Citi added a “downside 90-day catalyst watch” on shares of ResMed (RMD) while keeping a Buy rating on the name with an A$44 price target The growth in ResMed U.S. app downloads for the March quarter of up 4.1% year-over-year is tracking below the 7.2% U.S. devices sales growth consensus estimate for fiscal Q3, the analyst tells investors in a research note. The firm says U.S. devices account for one-third of ResMed revenue. Citi says the share price has historically reacted negatively to news flow on GLP-1s, and it opened the catalyst watch ahead of the Phase 3 readout for Orforglipron in type 2 diabetes, which is expected in Q2.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed announces availability of home sleep apnea test NightOwl
- ResMed price target lowered to $280 from $290 at BofA
- Resmed’s Resilience and Growth Prospects Amid Tariff Challenges: A Buy Recommendation
- Morgan Stanley Sees Near-Term Rally Ahead — Here Are 2 Stocks to Bet on It
- ResMed initiated with an Overweight at Morgan Stanley